Recent experimental studies have revealed that several peptides demonstrated promising performance in suppressing GC progression and metastasis by inhibiting angiogenesis, including Activin A, TCP-1, and JP3, but their application might be limited by challenges related to precise delivery and loss-of-target (Kaneda et al. 2011; Lu et al. 2017; Chen et al. 2020). This evidence concerns the gene TCP1 and gastric cancer.